Zilbrysq
Drug
UCB SA
Total Payments
$2.5M
Transactions
4,187
Doctors
1,502
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.9M | 3,924 | 1,501 |
| 2023 | $610,506 | 263 | 31 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.6M | 101 | 64.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $441,145 | 179 | 17.8% |
| Consulting Fee | $271,142 | 123 | 10.9% |
| Food and Beverage | $106,492 | 3,423 | 4.3% |
| Travel and Lodging | $61,447 | 361 | 2.5% |
Payments by Type
Research
$1.6M
101 transactions
General
$880,227
4,086 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis | UCB SA | $1.0M | 0 |
| A PHASE 3B, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF ZILUCOPLAN IN PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS SWITCHING FROM INTRAVENOUS COMPLEMENT COMPONENT 5 INHIBITORS TO SUBCUTANEOUS ZILUCOPLAN | UCB SA | $284,363 | 0 |
| A MULTICENTER, OPEN-LABEL, outpatient STUDY TO EVALUATE THE SAFE AND EFFECTIVE USE OF A ZILUCOPLAN AUTO‑INJECTOR COMBINATION PRODUCT FOR SUBCUTANEOUS SELF-ADMINISTRATION BY STUDY PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS | UCB SA | $256,869 | 0 |
| Phase 3, Multicenter, Randomized, Double-Blind, PBO-Controlled Study of Efficacy, Safety, and Tolerability of Zilucoplan in Subjects with Generalized Myasthenia Gravis | UCB SA | $26,611 | 0 |
| AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ACTIVITY OF ZILUCOPLAN IN PEDIATRIC STUDY PARTICIPANTS WITH ACETYLCHOLINE RECEPTOR ANTIBODY POSITIVE GENERALIZED MYASTHENIA GRAVIS | UCB SA | $15,750 | 0 |
| The Healey Platform Trial | UCB SA | $3,400 | 0 |
| A multicenter open label, uncontrolled, study to evaluate the pharmacokinetics, pharmacodynamics, safety, tolerability, and activity of Zilucoplan in pediatric study participants from two to less than eighteen years of age with Acetylcholine receptor antibody positive generalize myasthenia gravis. | UCB SA | $440.97 | 0 |
Top Doctors Receiving Payments for Zilbrysq — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Neurology | Amherst, NY | $5,121 | 9 |
| , M.D | Neuromuscular Medicine | Danville, PA | $5,060 | 7 |
| Margaret Naclerio | Physician Assistant | Boston, MA | $4,657 | 8 |
| , M.D | Student in an Organized Health Care Education/Training Program | Jackson, MS | $4,056 | 4 |
| , MD | Neurology | Audubon, NJ | $3,291 | 12 |
| , M.D | Neurology | Salt Lake City, UT | $3,125 | 2 |
| , M.D | Neurology | Portland, OR | $2,999 | 4 |
| , RPA-C | Surgical | Amherst, NY | $2,482 | 7 |
| , MD | Neuromuscular Medicine | Kansas City, KS | $2,475 | 1 |
| , M.D | Neurology | Boston, MA | $2,340 | 3 |
| , MD | Neurology | Burlington, VT | $1,920 | 2 |
| , MD | Neurology | Dallas, TX | $1,740 | 2 |
| , M.D | Neurology | Winston Salem, NC | $1,735 | 3 |
| , MD | Neurology | Los Angeles, CA | $1,593 | 12 |
| , M.D | Neurology | Coral Springs, FL | $1,581 | 8 |
| , MD, PHD | Neurology | Seattle, WA | $1,560 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | Albuquerque, NM | $1,558 | 5 |
| , M.D | Neurology | Yucca Valley, CA | $1,438 | 10 |
| , FNP-C | Family | Irvine, CA | $1,438 | 2 |
| , M.D | Neurology | Tallahassee, FL | $1,410 | 1 |
| , M.D | Neurology | Portland, OR | $1,410 | 1 |
| , M.D | Neurology | Burlington, VT | $1,410 | 1 |
| , MD | Neuromuscular Medicine | Wilmington, NC | $1,357 | 4 |
| , M.D | Neurology | Clearwater, FL | $1,289 | 8 |
| , MD | Neurology | Rochester, MN | $1,285 | 2 |
About Zilbrysq
Zilbrysq is a drug associated with $2.5M in payments to 1,502 healthcare providers, recorded across 4,187 transactions in the CMS Open Payments database. The primary manufacturer is UCB SA.
Payment data is available from 2023 to 2024. In 2024, $1.9M was paid across 3,924 transactions to 1,501 doctors.
The most common payment nature for Zilbrysq is "Unspecified" ($1.6M, 64.5% of total).
Zilbrysq is associated with 7 research studies, including "Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis" ($1.0M).